AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

TCRX · NASDAQ · Biotechnology

TScan Therapeutics

Develops TCR-engineered T-cell therapies for cancer through a T-cell receptor discovery platform.

$0.7535

After-hours close+0.00 (+0.15%)

At close$0.7524(+0.29%)

Something off on this page? Send us feedback.

Breakdown13F · Form 4

Institutions 53.16%Insiders —

Shares outstanding 61.07M · Float 55.39M · 90.7% free float

Insiders — no current Form 4 position.

A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
LYNX1 Capital Management LP	8.02M	13.13%	13F	May 4, 2026
BVF Inc/IL	5.56M	9.11%	13F	May 15, 2026
K2 HealthVentures Equity Trust LLC	3.60M	6.90%	13G	Feb 14, 2025
Biotechnology Value Fund L P	3.01M	5.40%	13G	May 15, 2026
Baker Bros. Advisors LP	2.78M	4.56%	13F	May 15, 2026

Institutions13F, as of Mar 31, 2026

58 holders · 32.47M shares · 11 new positions · 26 increased · 19 reduced · 13 closed

Holder	Shares	% outstanding	Chg q/q	Filed
LYNX1 Capital Management LP	8.02M	13.13%	0	May 4, 2026
BVF Inc/IL	5.56M	9.11%	+338.2K	May 15, 2026
Baker Bros. Advisors LP	2.78M	4.56%	0	May 15, 2026
Vanguard Capital Management LLC	2.15M	3.53%	+2.15Mnew	May 15, 2026
BlackRock, Inc.	1.84M	3.01%	−7.7K	May 13, 2026
Millennium Management LLC	1.46M	2.39%	+1.06M	May 15, 2026
Renaissance Technologies LLC	1.36M	2.23%	+223.7K	May 14, 2026
Deer Management Co. LLC	1.25M	2.04%	0	May 15, 2026

Beneficial owners13D/G · 5% or more, as filed

Holder	% of class	Shares	Form	Filed
Lynx1 Capital Management LP	15.00%	7.86M	13G	Aug 14, 2025 ↗
K2 HealthVentures Equity Trust LLC	6.90%	3.60M	13G	Feb 14, 2025 ↗
Biotechnology Value Fund L P	5.40%	3.01M	13G	May 15, 2026 ↗

InsidersForm 4

Insider	Role	Shares	Filed
Lynx1 Capital Management LP	10 percent owner	7.86M	Dec 23, 2025

3 ten-percent owners hold 14.00M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 10 people have not refiled in the last 18 months (3.15M shares), so they are not in the figure above

Latest trades

Date	Insider	Type	Shares	Avg price	Owned after
Dec 19, 2025	Lynx1 Capital Management LP10 percent owner	Purchase	80,069	$0.8989	7,937,416
Dec 22, 2025	Lynx1 Capital Management LP10 percent owner	Purchase	75,500	$0.9000	8,012,916
Dec 23, 2025	Lynx1 Capital Management LP10 percent owner	Purchase	6,232	$0.8989	8,019,148

CongressHouse and Senate disclosures

Not reported.